for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celon Pharma SA

CLNP.WA

Latest Trade

44.55PLN

Change

0.25(+0.56%)

Volume

7,688

Today's Range

44.40

 - 

44.80

52 Week Range

28.25

 - 

51.10

As of on the Warsaw Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
44.30
Open
44.40
Volume
7,688
3M AVG Volume
0.21
Today's High
44.80
Today's Low
44.40
52 Week High
51.10
52 Week Low
28.25
Shares Out (MIL)
45.00
Market Cap (MIL)
1,993.50
Forward P/E
82.80
Dividend (Yield %)
0.38

Next Event

Celon Pharma SA Annual Shareholders Meeting

Latest Developments

More

Celon Pharma Q3 Net Profit Down At 2.1 Mln Zlotys

Celon Pharma H1 Net Profit Down At 8.2 Mln Zlotys

Celon Pharma Says Receives Patent From Japanese Patent Office Regarding Inhibitory FGFR

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celon Pharma SA

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Industry

Biotechnology & Drugs

Contact Info

ul. Ogrodowa 2A, Kielpin

+48.22.7515933

https://celonpharma.com/

Executive Leadership

Robert Stanislaw Rzeminski

Chairman of the Supervisory Board

Maciej Wieczorek

Chairman of the Management Board, Chief Executive Officer

Iwona Maria Giedronowicz

Member of the Management Board, Chief Financial Officer

Bogdan Szczepan Manowski

Member of the Management Board, Director for Business Development

Krzysztof Robert Kaczmarczyk

Independent Member of the Supervisory Board

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, PLN)

2018

0.1K

2019(E)

0.1K
EPS (PLN)

2018

0.660

2019(E)

0.535
Price To Earnings (TTM)
87.75
Price To Sales (TTM)
16.88
Price To Book (MRQ)
4.51
Price To Cash Flow (TTM)
45.86
Total Debt To Equity (MRQ)
0.37
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
4.22
Return on Equity (TTM)
4.00

Latest News

Latest News

BRIEF-Celon Pharma Completes Administration Of Drug Candidate In Phase I Clinical Test

* SAID ON THURSDAY THAT IT HAS COMPLETED ADMINISTRATION OF DRUG CANDIDATE IN PHASE I OF CLINICAL TEST OF A DRUG BASED ON PDE10A INHIBITOR, DEVELOPED IN THE TREATMENT OF PSYCHOTIC AND NEUROMOTOR DISORDERS - CPL500036

BRIEF-Celon Pharma Updates On Market Status Of Valzek Drug

* SAID ON THURSDAY THAT CHIEF PHARMACEUTICAL INSPECTORATE HAS DECIDED TO RESTORE TRADING OF MORE THAN 200 SERIES OF VALZEK DRUG, IN 80 MG AND 160 MG DOSES, PREVIOUSLY SUSPENDED IN THE WHOLE COUNTRY AS OF AUGUST 2018

BRIEF-Celon Pharma Q1 Net Profit Down At 6.5 Mln Zlotys

* REPORTED ON MONDAY Q1 NET PROFIT OF 6.5 MILLION ZLOTYS VERSUS 7.5 MILLION ZLOTYS YEAR AGO

BRIEF-Celon Pharma FY Net Profit Up At 29.7 Mln Zlotys

* REPORTED ON TUESDAY NET PROFIT OF 29.7 MILLION ZLOTYS VERSUS 25.6 MILLION ZLOTYS YEAR AGO

BRIEF-Celon Pharma Gets Patent For PDE10A Inhibitors In China

* SAID ON THURSDAY IT HAS BEEN GRANTED PATENT FOR PHOSPHODIESTERASE 10A INHIBITORS (PDE10A) BY CHINA NATIONAL INTELLECTUAL PROPERTY ADMINISTRATION (CNIPA)

BRIEF-Celon Pharma Projects Get Recommendation For Co-Financing

* SAID ON THURSDAY THAT TWO COMPANY'S APPLICATIONS FOR CO-FINANCING OF PROJECTS HAVE BEEN RECOMMENDED BY NATIONAL CENTER FOR RESEARCH AND DEVELOPMENT FOR CO-FINANCING

BRIEF-Celon Pharma Granted Patent In The US

* SAID ON SUNDAY THAT IT HAS BEEN GRANTED PATENT FOR PDE10A INHIBITORS AND THEIR USE IN TREATMENT OF NEUROLOGICAL AND PSYCHOTIC DISEASES AND DISORDERS IN THE US

BRIEF- Celon Pharma Gets Patent For PI3K Inhibitors In U.S.

* SAID ON TUESDAY THAT IT RECEIVED PATENT IN U.S. FOR PI3K INHIBITORS, WHICH ARE USED IN TREATMENT OF IMMUNOLOGICAL DISEASES, INFLAMMATORY DISEASES AND IN ONCOLOGY THERAPIES

BRIEF-Celon Pharma Registers Salmex In Czech Republic, Slovakia

* SAYS RECEIVED INFORMATION ABOUT POSITIVE COMPLETION OF MUTUAL RECOGNITION PROCESS FOR 'SALMEX' DRUG FOR CZECH AND SLOVAKIAN MARKETS

BRIEF-Celon Pharma Plans FY 2017 Dividend Of 0.17 Zloty/Share

* MANAGEMENT PROPOSES FY 2017 DIVIDEND OF 0.17 ZLOTY PER SHARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celon Pharma FY Net Profit Down At 25.6 Million Zlotys

* SAID ON MONDAY THAT ITS FY NET PROFIT WAS 25.6 MILLION ZLOTYS VERSUS 37.8 MILLION ZLOTYS YEAR AGO

BRIEF-Celon Pharma Signs Deal For Industrial Development And Production For Clinical Trial Of Anti-VEGF Protein

* SIGNS CONTRACT WITH BIOTECHPHARMA FOR INDUSTRIAL DEVELOPMENT AND PRODUCTION FOR CLINICAL TRIAL IN GMP QUALITY OF ANTI-VEGF PROTEIN

BRIEF-Celon Pharma Supervisory Board Chairman Resigns

* MACIEJ ANDRZEJ KRASINSKI RESIGNS FROM HIS POST AS CHAIRMAN OF CO'S SUPERVISORY BOARD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celon Pharma Gets 24.7 Mln Zloty Financing For Type II Diabetes Therapy

* SIGNS DEAL WITH NCBIR ON 24.7 MILLION ZLOTY FINANCING FOR PROJECT RELATED TO TYPE II DIABETES THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celon Pharma To Get PLN 24.7 Mln Financing For Development Of Biosimilar Drug

* SIGNS AGREEMENT FOR FUNDING OF ITS PROJECT WITH NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT

BRIEF-Celon Pharma Plans To Place Salmex On Scandinavian Markets In H1 2018

* INFORMS THAT REGISTRATION PROCEDURE OF SALMEX DRUG IN SCANDINAVIAN COUNTRIES ENDS POSITIVELY

BRIEF-Celon Pharma Can Start Phase I Clinical Study Of Esketamine-Based Drug

* GETS PERMISSION FOR STARTING PHASE I CLINICAL STUDY FOR ITS DRUG BASED ON ESKETAMINE

BRIEF-Celon Pharma to get 22.9 mln zloty financing from NCBiR

* SIGNS DEAL WITH NCBIR ON 22.9 MILLION ZLOTY FINANCING OF CO'S PROJECT RELATED TO NERVOUS SYSTEM DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Celon Pharma Q3 net profit down at 4.9 mln zlotys

* Q3 REVENUE 24.2 MILLION ZLOTYS VERSUS 22.4 MILLION ZLOTYS YEAR AGO

BRIEF-Celon Pharma to get 25.6 mln zloty financing for its project

* SIGNS DEAL WITH NCBIR UNDER WHICH CO TO GET 25.6 MILLION ZLOTY FINANCING FOR ITS PROJECT Source text: http://bit.ly/2yOKm52 Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up